InMed’s CEO Eric A. Adams featured at Benzinga’s Healthcare and Biotech Breakthroughs Event.
Host Zunaid Suleman spoke with Eric Adams about InMed’s drug candidate INM-901 for Alzheimer’s disease and the exciting preclinical research that is showing how this small molecule compound is reducing neuroinflammation, providing neuroprotection of the neurons and promoting the growth of neurites which are the branches extending from the neurons that enable cell-to-cell communication. This extension of these neurites, a process called neuritogenesis, signifies enhanced neuronal function and may be important in reversing damage caused by Alzheimer’s disease. The preclinical studies of INM-901 are also showing the potential to reduce in amyloid-beta plaque. While amyloid-beta plaques and tau tangles are the hallmarks of Alzheimer’s disease, there are several pathologies that lead to the development and progression of Alzheimer’s disease. Preclinical studies to date are demonstrating promising results that indicate InMed’s INM-901 may be able to address multiple pathologies related to this destructive disease.
InMed’s studies demonstrate that INM-901 targets several biological pathways associated with Alzheimer’s disease. In well-recognized in vivo Alzheimer’s disease study models, it was observed that INM-901 is a preferential signaling agonist of cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2) and impacts the peroxisome proliferator-activated receptor (PPAR) signaling pathway.
Originally aired on June 20th via Benzinga. Watch full interview here.
